Pharmacomechanical Thrombolysis of Symptomatic Acute and Subacute Deep Vein Thrombosis with a Rotational Thrombectomy Device

Köksoy, Cüneyt; Yılmaz, Muhammet Fatih; Başbuğ, Hamit Serdar; Çalık, Eyüp Serhat; Erkut, Bilgehan; Kayğın, Mehmet Ali; Peker, Ahmet; Sanlidilek, Umman

doi:10.1016/j.jvir.2014.08.018

Cited by 46 publications

(38 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More recent reports have shown that the Cleaner thrombectomy device (Argon Medical Devices, Plano, Texas, USA) (20) and the Arrow-Trerotola device (Arrow, Reading, PA, USA) (21) are effective in treating acute DVT. Similarly, small series and retrospective studies comparing pharmacomechanical thrombectomy to CDPT suggest that similar efficacy can be achieved by pharmacomechanical thrombectomy without the costs of ICU monitoring and decreased hospital stays (22) and that PTS may be decreased with pharmacomechanical thrombectomy at 1 year (23).…”

Section: Discussionmentioning

confidence: 99%

Catheter directed interventions for acute deep vein thrombosis

Kohi

Kohlbrenner

Kolli

et al. 2016

Cardiovasc. Diagn. Ther.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Catheter directed interventions for acute deep vein thrombosis

Kohi

Kohlbrenner

Kolli

et al. 2016

Cardiovasc. Diagn. Ther.

View full text Add to dashboard Cite

“…Although the long-term results of this treatment have not been examined in randomized controlled studies, successful PMT implementations have been reported in observational studies (6).…”

Section: Discussionmentioning

confidence: 99%

Pharmacomechanical Thrombolytic Treatment in Symptomatic Acute and Subacute Deep Vein Thrombosis

et al. 2016

View full text Add to dashboard Cite

Background: In this study, we shared the implementation success and clinical results for 38 patients treated with the cleaner™ pharmacomechanical thrombectomy device. Objectives: The impact and results of pharmacomechanical thrombectomy treatment on patients with deep vein thrombosis in the symptomatic acute and subacute phases were assessed. Patients and Methods: Pharmacomechanical thrombectomy treatment was applied in a single session for 38 patients with lower extremity deep vein thrombosis in the acute and subacute phases between May 2012 and June 2014. Venography was performed and each assessment was made based on lysis rates and clinical results. Results: Deep vein thrombosis was found in the left lower extremity in 25 patients (65%) and in the right lower extremity in 13 patients (35%). No patient was found to have bilateral deep vein thrombosis. Thrombus localization was in the iliofemoral area in 17 patients (44%), the iliocaval area in three patients (8%), and the femoropopliteal area in 18 patients (56%). When thrombus resolution was assessed at the end of the process, grade III and grade II lysis was achieved in 36 (94%) out of 38 patients. Complete resolution was achieved in 28 patients (74%) in the acute and subacute groups. Conclusion: Pharmacomechanical thrombectomy provides very satisfactory results in a single procedure, as a new method in the treatment of acute and subacute deep vein thrombosis.

show abstract

“…High success rates of clot lysis have been reported in studies assessing the effect of combining CDT with PMT, balloon maceration, or aspiration thrombectomy [161][162][163][164][165][166][167]. Although these methods are generally considered as safe treatments with lower dose and shorter treatment time, they have not been documented by large randomized controlled trials.…”

Section: Recommendationmentioning

confidence: 99%